Kök hücre transplantasyonlarında myeloid hücreler üzerinde bulunan GM-CSF reseptör sayılarının prediktif değerinin araştırılması

Peripheral hematopoietic stem cell transplantation is a method used in the treatment of many diseases, especially hematological malignancies. With the method called apheresis, the patient's own stem cells (autologous) or stem cells from a matched healthy donor (allogeneic) are collected and transplantation is performed under appropriate conditions. Evaluation of the quality of the received apheresis product is very important in terms of both measuring the collection efficiency and monitoring the transplantation dynamics. Although the gold standard CD34+ stem cell count is accepted today, the evaluation and calculation criteria differ between centers. The aim of this study was to determine the number and expression of GM-CSFR (CD116) and to measure its usability as an additional predictive parameter to CD34 in the evaluation of the quality of the apheresis product. The percentage of CD116, Mean Fluorescent Intensity (MFI) and GM-CSF receptor number were determined in apheresis products of autologous and allogeneic donors and in peripheral blood of healthy donors who did not receive Granulocyte Colony-Stimulating Factor (G-CSF). Obtained data were compared both between myeloid cells and between study groups. While the percentage of CD116 did not show a significant difference both on myeloid cells and between groups, MFI of CD116 and GM-CSF receptor numbers were detected on monocytes (mean MFI value 4,8, mean GM-CSFR number 9.560 ABC/Cell) with the highest concentration in myeloid cells, and in apheresis products of allogeneic donors among the groups (mean MFI value 5,0, mean GM-CSFR number 9.965 ABC/Cell). There was no significant correlation between CD34 and CD116 in apheresis products, but the highest MFI of CD116 (mean 3,79) and GM-CSF receptor number (mean 7.506 ABC/Cell) were observed in apheresis products from allogeneic donors with the highest leukocyte (mean 204.513/µL) and platelet (mean 165 x 103/µL) counts. In autologous donors, a positive correlation was found between the percentage of CD116 and the number of WBCs in the apheresis product (p = 0,008). In conclusion, CD116 can be used as a predictive factor in evaluating the quality of apheresis products by providing information about myeloid cell content.